Speeding up drug discovery – Glyconet & 48Hour Discovery
48Hour Discovery and Glyconet were recently featured by Global News https://globalnews.ca/video/8705661/health-matters-speeding-up-drug-discovery-new-covid-19-variant-now-dominant-in-alberta/
48HD uses genetically encoded phage displayed peptide and peptide derived libraries to discover target ligands. With over one billion medium sized peptides (200-3000 Dalton), the library ensures a “sweet spot” in protein-ligand recognition, unlike small molecule and antibody-based therapeutics. Four in-house encoded, proprietary libraries are currently available for screening services.
We accelerate discovery to find new and better drugs. Our patented technology, which combines phage display and next generation sequencing, can screen billions of unique peptides within weeks.
48 Hour Discovery has a powerful new technology platform for peptide-based drug discovery. Our technology can discover drug leads in days rather than months.
Our unique platform enables the rapid identification of both standard and macrocyclic peptides, which exhibit excellent potency, selectivity, and GI stability for oral delivery.
Drug discovery is a complex process that can cost billions of dollars but there are innovations at every step of the process that make this process more streamlined and thereby lower its cost
Ratmir Derda – CEO 48Hour Discovery
With 48Hour Discovery’s technology—part chemistry, part artificial intelligence—potential drug targets are retrieved using the interaction between target proteins from, for instance, a cancer cell and a molecule library in a test tube.
We use phage display and high throughput next-generation sequencing to identify peptide ligands with high affinity for promising drug targets from billion-scale libraries of molecules.
Single-round screening is applied when protein targets have defined binding sites e.g. antibodies. The outcome of such screening are linear epitope mapping or immunoprofiling. We recommend clients use our in-house linear or cyclic libraries
Multi-round screening is used to probe protein-protein interactions, or when targets are more complex, e.g. with shallow binding sites, or targets that form complex. In this case, we recommend clients using our cyclic, bicyclic, or GE-FBD/customized libraries.
We operate a proprietary cloud database service to store all results. This service enables access to results from anywhere in the world, with any device. In addition, search data that some academic partners have made public is available.
Founder & CEO
Director of Discovery
VP of Data Science and Information Technology
VP of Finance & Business Development
VP of Research and Development
VP OF MARKETING
48Hour Discovery and Glyconet were recently featured by Global News https://globalnews.ca/video/8705661/health-matters-speeding-up-drug-discovery-new-covid-19-variant-now-dominant-in-alberta/
As with genomics 20 years ago, glycomics is at a critical stage, a tipping point. Glycomics is expected…
The goal of the collaboration is to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumours.…
We accelerate discovery to find new and better drugs leads in days rather than months.